Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

ADAMTS9 (ADAM metallopeptidase with thrombospondin type 1 motif, 9)

Written2013-12Sawako Yoshina, Shohei Mitani
Department of Physiology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

(Note : for Links provided by Atlas : click)

Identity

Alias_namesa disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif
Alias_symbol (synonym)KIAA1312
Other alias
HGNC (Hugo) ADAMTS9
LocusID (NCBI) 56999
Atlas_Id 577
Location 3p14.1  [Link to chromosome band 3p14]
Location_base_pair Starts at 64515655 and ends at 64687689 bp from pter ( according to hg19-Feb_2009)  [Mapping ADAMTS9.png]
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
ADAMTS9 (3p14.1) / CHL1 (3p26.3)ADAMTS9 (3p14.1) / SYNPR (3p14.2)ADAMTS9 (3p14.1) / ULK4 (3p22.1)
ZNF619 (3p22.1) / ADAMTS9 (3p14.1)

DNA/RNA

Description The human ADAMTS9 gene is composed of 40 exons spanning a genomic region of about 172 kbp. The open reading frame of the coding region is 5808 bp.
Pseudogene No pseudogene reported.

Protein

 
  Diagram of the human ADAMTS9 protein.
Description ADAMTS9 is composed of a signal peptide, a propeptide, a metalloproteinase domain, a disintegrin-like domain, thrombospondin type 1-like repeats, a cystein-rich domain, a spacer domain, and a unique C-terminal domain (Somerville et al., 2003). A unique C-terminal domain was named as GON domain. The GON domain functions in the ER for protein transport from the ER to the Golgi (Yoshina et al., 2012). N-linked glycosylation of ADAMTS9 propeptide is found to be essential for ADAMTS9 secretion (Koo et al., 2007). ADAMTS9 is processed by furin extracellularly but not in the secretory pathway (Koo et al., 2006). Following furin processing, mature ADAMTS9 is released from the cell surface (Koo et al., 2007).
ADAMTS9 is required for early mouse development. ADAMTS9 null mice die before gastrulation. ADAMTS9+/- mice develop anomalous eye such as corneal clouding, corneal neovascularisation, and adhesions of the lens and iris to the cornea (Koo et al., 2010).
Expression ADAMTS9 is found in adult human ovary, pancreas, heart, kidney, lung, placenta, and skeletal muscle. ADAMTS9 is found in fetal brain, heart, kidney, lung, liver, skeletal muscle, spleen and thymus. According to northern blot analysis, the highest mRNA levels are found in heart, placenta, and skeletal muscle (Clark et al., 2000; Somerville et al., 2003). ADAMTS9 is expressed in microvascular endothelial cells (Koo et al., 2010).
Following stimulation with TNFalpha, ADAMTS9 mRNA expression was enhanced in a human retinal pigment epithelial cell line (ARPE-19) (Bevitt et al., 2003). In a human chondrosarcoma cell line (OUMS-27) and human chondrocytes, exposure to IL-1 beta or TNF alpha upregulate ADAMTS9 mRNA expression (Demircan et al., 2005). Induction of ADAMTS9 mRNA by IL-1beta was reported to occur via NFATc binding to the ADAMTS9 promoter in the OUMS-27 and in human chondrocyte (Yaykasli et al., 2009). In the human lung carcinoma epithelial cell line (A549), exposure to TGF- beta or IL-13 or Epstein-Barr virus infection led to enhanced ADAMTS9 mRNA expression. IL-4 exposure had no effect on the expression of ADAMTS9 in A549 (Keating et al., 2006).
Localisation ADAMTS9 is present at the plasma membrane and the endoplasmic reticulum (Somerville et al., 2003; Yoshina et al., 2012).
Function ADAMTS9 cleaves aggrecan and versican (Somerville et al., 2003). ADAMTS9 is involved in cell migration and inhibition of angiogenesis (Koo et al., 2010).
ADAMTS9 is implicated in the transport from the endoplasmic reticulum to the Golgi. This function is GON-domain dependent but protease activity independent (Yoshina et al., 2012).
Homology ADAMTS9 and ADAMTS20 have the identical domain organization and exon structure and a similar primaly sequence. The unique C-terminal domain, GON domain, is highly similar in ADAMTS9 and ADAMTS20 (Somerville et al., 2003).

Mutations

Note A downregulation of ADAMTS9 has been observed in some carcinoma that is induced by aberrant methylation of the gene.
The major C-risk allele of rs4607103 near ADAMTS9, conferring increased risk of type 2 diabetes.

Implicated in

Note
  
Entity Esophageal squamous cell carcinoma
Note Complete loss or downregulation of ADAMTS9 gene expression was found in 15 out of 16 esophageal carcinoma cell lines. Promoter hypermethylation was involved in gene downregulation. Downregulation of ADAMTS9 was also found in primary esophageal tumor tissues from Hong Kong and from the high-risk region of Henan (Lo et al., 2007). Downregulation of ADAMTS9 expression led to tumorigenesis. Overexpression of ADAMTS9 induced suppression of tumor formation and angiogenesis in esophageal carcinoma cell line (Lo et al., 2010).
  
  
Entity Nasopharyngeal carcinoma
Note ADAMTS9 was downregulated in nasopharyngeal carcinoma cell lines. The mechanism of ADAMTS9 gene inactivation was attributed to promoter hypermethylation (Lung et al., 2008). Downregulation of ADAMTS9 expression led to tumorigenesis. Overexpression of ADAMTS9 induced suppression of tumor formation and angiogenesis in nasopharyngeal carcinoma cell line (Lo et al., 2010).
  
  
Entity Colorectal cancer
Note The frequency of ADAMTS9 promoter methylation in primary colorectal cancers was significantly higher than in normal tissues (Zhang et al., 2010).
  
  
Entity Gastric cancer
Note The frequency of ADAMTS9 promoter methylation in primary gastric cancers was significantly higher than in normal tissues (Zhang et al., 2010; Du et al., 2013). ADAMTS9 contributes to the suppression of tumorigenesis by decreasing cell proliferation, inducing cell apoptosis and inhibiting angiogenesis through regulating AKT/mTOR signaling pathway (Du et al., 2013).
  
  
Entity Pancreatic cancer
Note The frequency of ADAMTS9 promoter methylation in primary pancreatic cancers was significantly higher than in normal tissues (Zhang et al., 2010).
  
  
Entity Type II diabetes
Note Genome-wide assosiation studies (GWAS) linked a marker near the ADAMTS9 locus to type II diabetes (Zeggini et al., 2008). The major C allele of rs4607103, located upstream of ADAMTS9, was established as a diabetes risk variant in GWAS. rs4607103 is associated with a decrease in insulin sensitivity of peripheral tissues (Boesgaard et al., 2009; Trombetta et al., 2013).
  

Bibliography

Expression of ADAMTS metalloproteinases in the retinal pigment epithelium derived cell line ARPE-19: transcriptional regulation by TNFalpha.
Bevitt DJ, Mohamed J, Catterall JB, Li Z, Arris CE, Hiscott P, Sheridan C, Langton KP, Barker MD, Clarke MP, McKie N.
Biochim Biophys Acta. 2003 Apr 15;1626(1-3):83-91.
PMID 12697333
 
Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients--EUGENE2 study.
Boesgaard TW, Gjesing AP, Grarup N, Rutanen J, Jansson PA, Hribal ML, Sesti G, Fritsche A, Stefan N, Staiger H, Haring H, Smith U, Laakso M, Pedersen O, Hansen T; EUGENE2 Consortium.
PLoS One. 2009 Sep 30;4(9):e7236. doi: 10.1371/journal.pone.0007236.
PMID 19789630
 
ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family.
Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA.
Genomics. 2000 Aug 1;67(3):343-50.
PMID 10936055
 
ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes.
Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, Apte SS, Ninomiya Y.
Arthritis Rheum. 2005 May;52(5):1451-60.
PMID 15880812
 
ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.
Du W, Wang S, Zhou Q, Li X, Chu J, Chang Z, Tao Q, Ng EK, Fang J, Sung JJ, Yu J.
Oncogene. 2013 Jul 11;32(28):3319-28. doi: 10.1038/onc.2012.359. Epub 2012 Aug 20.
PMID 22907434
 
Microarray identifies ADAM family members as key responders to TGF-beta1 in alveolar epithelial cells.
Keating DT, Sadlier DM, Patricelli A, Smith SM, Walls D, Egan JJ, Doran PP.
Respir Res. 2006 Sep 1;7:114.
PMID 16948840
 
ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells.
Koo BH, Coe DM, Dixon LJ, Somerville RP, Nelson CM, Wang LW, Young ME, Lindner DJ, Apte SS.
Am J Pathol. 2010 Mar;176(3):1494-504. doi: 10.2353/ajpath.2010.090655. Epub 2010 Jan 21.
PMID 20093484
 
Regulation of ADAMTS9 secretion and enzymatic activity by its propeptide.
Koo BH, Longpre JM, Somerville RP, Alexander JP, Leduc R, Apte SS.
J Biol Chem. 2007 Jun 1;282(22):16146-54. Epub 2007 Apr 2.
PMID 17403680
 
Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9.
Lo PH, Leung AC, Kwok CY, Cheung WS, Ko JM, Yang LC, Law S, Wang LD, Li J, Stanbridge EJ, Srivastava G, Tang JC, Tsao SW, Lung ML.
Oncogene. 2007 Jan 4;26(1):148-57. Epub 2006 Jun 26.
PMID 16799631
 
Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis.
Lo PH, Lung HL, Cheung AK, Apte SS, Chan KW, Kwong FM, Ko JM, Cheng Y, Law S, Srivastava G, Zabarovsky ER, Tsao SW, Tang JC, Stanbridge EJ, Lung ML.
Cancer Res. 2010 Jul 1;70(13):5567-76. doi: 10.1158/0008-5472.CAN-09-4510. Epub 2010 Jun 15.
PMID 20551050
 
Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma.
Lung HL, Lo PH, Xie D, Apte SS, Cheung AK, Cheng Y, Law EW, Chua D, Zeng YX, Tsao SW, Stanbridge EJ, Lung ML.
Int J Cancer. 2008 Jul 15;123(2):401-8. doi: 10.1002/ijc.23528.
PMID 18449890
 
Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1.
Somerville RP, Longpre JM, Jungers KA, Engle JM, Ross M, Evanko S, Wight TN, Leduc R, Apte SS.
J Biol Chem. 2003 Mar 14;278(11):9503-13. Epub 2003 Jan 3.
PMID 12514189
 
PPARG2 Pro12Ala and ADAMTS9 rs4607103 as "insulin resistance loci" and "insulin secretion loci" in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4.
Trombetta M, Bonetti S, Boselli ML, Miccoli R, Trabetti E, Malerba G, Pignatti PF, Bonora E, Del Prato S, Bonadonna RC.
Acta Diabetol. 2013 Jun;50(3):401-8. doi: 10.1007/s00592-012-0443-9. Epub 2012 Nov 17.
PMID 23161442
 
ADAMTS9 activation by interleukin 1 beta via NFATc1 in OUMS-27 chondrosarcoma cells and in human chondrocytes.
Yaykasli KO, Oohashi T, Hirohata S, Hatipoglu OF, Inagawa K, Demircan K, Ninomiya Y.
Mol Cell Biochem. 2009 Mar;323(1-2):69-79. doi: 10.1007/s11010-008-9965-4. Epub 2008 Dec 4.
PMID 19052845
 
Identification of a novel ADAMTS9/GON-1 function for protein transport from the ER to the Golgi.
Yoshina S, Sakaki K, Yonezumi-Hayashi A, Gengyo-Ando K, Inoue H, Iino Y, Mitani S.
Mol Biol Cell. 2012 May;23(9):1728-41. doi: 10.1091/mbc.E11-10-0857. Epub 2012 Mar 14.
PMID 22419820
 
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.
Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Bostrom KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, Jorgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V, Marvelle AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ, Sandbaek A, Shields B, Sjogren M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ; Wellcome Trust Case Control Consortium, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso I, Hattersley AT, Collins FS, Groop L, McCarthy MI, Boehnke M, Altshuler D.
Nat Genet. 2008 May;40(5):638-45. doi: 10.1038/ng.120. Epub 2008 Mar 30.
PMID 18372903
 
High-resolution melting analysis of ADAMTS9 methylation levels in gastric, colorectal, and pancreatic cancers.
Zhang C, Shao Y, Zhang W, Wu Q, Yang H, Zhong Q, Zhang J, Guan M, Yu B, Wan J.
Cancer Genet Cytogenet. 2010 Jan 1;196(1):38-44. doi: 10.1016/j.cancergencyto.2009.08.016.
PMID 19963134
 

Citation

This paper should be referenced as such :
Yoshina, S ; Mitani, S
ADAMTS9 (ADAM metallopeptidase with thrombospondin type 1 motif, 9)
Atlas Genet Cytogenet Oncol Haematol. 2014;18(7):497-499.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/ADAMTS9ID577ch3p14.html


External links

Nomenclature
HGNC (Hugo)ADAMTS9   13202
Cards
AtlasADAMTS9ID577ch3p14
Entrez_Gene (NCBI)ADAMTS9  56999  ADAM metallopeptidase with thrombospondin type 1 motif 9
Aliases
GeneCards (Weizmann)ADAMTS9
Ensembl hg19 (Hinxton)ENSG00000163638 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000163638 [Gene_View]  chr3:64515655-64687689 [Contig_View]  ADAMTS9 [Vega]
ICGC DataPortalENSG00000163638
TCGA cBioPortalADAMTS9
AceView (NCBI)ADAMTS9
Genatlas (Paris)ADAMTS9
WikiGenes56999
SOURCE (Princeton)ADAMTS9
Genetics Home Reference (NIH)ADAMTS9
Genomic and cartography
GoldenPath hg38 (UCSC)ADAMTS9  -     chr3:64515655-64687689 -  3p14.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)ADAMTS9  -     3p14.1   [Description]    (hg19-Feb_2009)
EnsemblADAMTS9 - 3p14.1 [CytoView hg19]  ADAMTS9 - 3p14.1 [CytoView hg38]
Mapping of homologs : NCBIADAMTS9 [Mapview hg19]  ADAMTS9 [Mapview hg38]
OMIM605421   
Gene and transcription
Genbank (Entrez)AB037733 AF261918 AF488803 AK124945 AK300357
RefSeq transcript (Entrez)NM_001318781 NM_182920
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)ADAMTS9
Cluster EST : UnigeneHs.656071 [ NCBI ]
CGAP (NCI)Hs.656071
Alternative Splicing GalleryENSG00000163638
Gene ExpressionADAMTS9 [ NCBI-GEO ]   ADAMTS9 [ EBI - ARRAY_EXPRESS ]   ADAMTS9 [ SEEK ]   ADAMTS9 [ MEM ]
Gene Expression Viewer (FireBrowse)ADAMTS9 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)56999
GTEX Portal (Tissue expression)ADAMTS9
Human Protein AtlasENSG00000163638-ADAMTS9 [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9P2N4   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9P2N4  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9P2N4
Splice isoforms : SwissVarQ9P2N4
Catalytic activity : Enzyme3.4.24.- [ Enzyme-Expasy ]   3.4.24.-3.4.24.- [ IntEnz-EBI ]   3.4.24.- [ BRENDA ]   3.4.24.- [ KEGG ]   
PhosPhoSitePlusQ9P2N4
Domaine pattern : Prosite (Expaxy)ADAM_MEPRO (PS50215)    GON (PS51046)    TSP1 (PS50092)    ZINC_PROTEASE (PS00142)   
Domains : Interpro (EBI)ADAM_spacer1    MetalloPept_cat_dom    Pept_M12B_GON-ADAMTSs    Peptidase_M12B    Peptidase_M12B_ADAM-TS    Peptidase_M12B_N    TSP1_rpt   
Domain families : Pfam (Sanger)ADAM_spacer1 (PF05986)    GON (PF08685)    Pep_M12B_propep (PF01562)    Reprolysin (PF01421)    TSP_1 (PF00090)   
Domain families : Pfam (NCBI)pfam05986    pfam08685    pfam01562    pfam01421    pfam00090   
Domain families : Smart (EMBL)TSP1 (SM00209)  
Conserved Domain (NCBI)ADAMTS9
DMDM Disease mutations56999
Blocks (Seattle)ADAMTS9
SuperfamilyQ9P2N4
Human Protein Atlas [tissue]ENSG00000163638-ADAMTS9 [tissue]
Peptide AtlasQ9P2N4
HPRD05662
IPIIPI00329771   IPI00220986   IPI00748386   IPI00909066   IPI00795595   IPI00946344   
Protein Interaction databases
DIP (DOE-UCLA)Q9P2N4
IntAct (EBI)Q9P2N4
FunCoupENSG00000163638
BioGRIDADAMTS9
STRING (EMBL)ADAMTS9
ZODIACADAMTS9
Ontologies - Pathways
QuickGOQ9P2N4
Ontology : AmiGOmetalloendopeptidase activity  proteinaceous extracellular matrix  extracellular space  endoplasmic reticulum  proteolysis  glycoprotein catabolic process  multicellular organism development  metallopeptidase activity  zinc ion binding  cell surface  protein transport  vesicle-mediated transport  extracellular matrix  positive regulation of melanocyte differentiation  
Ontology : EGO-EBImetalloendopeptidase activity  proteinaceous extracellular matrix  extracellular space  endoplasmic reticulum  proteolysis  glycoprotein catabolic process  multicellular organism development  metallopeptidase activity  zinc ion binding  cell surface  protein transport  vesicle-mediated transport  extracellular matrix  positive regulation of melanocyte differentiation  
REACTOMEQ9P2N4 [protein]
REACTOME PathwaysR-HSA-5173214 [pathway]   
NDEx NetworkADAMTS9
Atlas of Cancer Signalling NetworkADAMTS9
Wikipedia pathwaysADAMTS9
Orthology - Evolution
OrthoDB56999
GeneTree (enSembl)ENSG00000163638
Phylogenetic Trees/Animal Genes : TreeFamADAMTS9
HOVERGENQ9P2N4
HOGENOMQ9P2N4
Homologs : HomoloGeneADAMTS9
Homology/Alignments : Family Browser (UCSC)ADAMTS9
Gene fusions - Rearrangements
Fusion : MitelmanADAMTS9/CHL1 [3p14.1/3p26.3]  
Fusion : MitelmanADAMTS9/SYNPR [3p14.1/3p14.2]  [t(3;3)(p14;p14)]  
Fusion : MitelmanADAMTS9/ULK4 [3p14.1/3p22.1]  [t(3;3)(p14;p22)]  
Fusion: TCGA_MDACCADAMTS9 3p14.1 CHL1 3p26.3 LUAD
Fusion: TCGA_MDACCADAMTS9 3p14.1 SYNPR 3p14.2 PRAD
Fusion: TCGA_MDACCADAMTS9 3p14.1 ULK4 3p22.1 LUAD
Tumor Fusion PortalADAMTS9
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerADAMTS9 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)ADAMTS9
dbVarADAMTS9
ClinVarADAMTS9
1000_GenomesADAMTS9 
Exome Variant ServerADAMTS9
ExAC (Exome Aggregation Consortium)ENSG00000163638
GNOMAD BrowserENSG00000163638
Genetic variants : HAPMAP56999
Genomic Variants (DGV)ADAMTS9 [DGVbeta]
DECIPHERADAMTS9 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisADAMTS9 
Mutations
ICGC Data PortalADAMTS9 
TCGA Data PortalADAMTS9 
Broad Tumor PortalADAMTS9
OASIS PortalADAMTS9 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICADAMTS9  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDADAMTS9
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch ADAMTS9
DgiDB (Drug Gene Interaction Database)ADAMTS9
DoCM (Curated mutations)ADAMTS9 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)ADAMTS9 (select a term)
intoGenADAMTS9
NCG5 (London)ADAMTS9
Cancer3DADAMTS9(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM605421   
Orphanet
DisGeNETADAMTS9
MedgenADAMTS9
Genetic Testing Registry ADAMTS9
NextProtQ9P2N4 [Medical]
TSGene56999
GENETestsADAMTS9
Target ValidationADAMTS9
Huge Navigator ADAMTS9 [HugePedia]
snp3D : Map Gene to Disease56999
BioCentury BCIQADAMTS9
ClinGenADAMTS9
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD56999
Chemical/Pharm GKB GenePA24553
Clinical trialADAMTS9
Miscellaneous
canSAR (ICR)ADAMTS9 (select the gene name)
Probes
Litterature
PubMed65 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineADAMTS9
EVEXADAMTS9
GoPubMedADAMTS9
iHOPADAMTS9
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Nov 20 21:08:03 CET 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.